Background: Patients with ST-segment elevation myocardial infarction (STEMI) are often pretreated with unfractionated heparin (UFH) before a primary percutaneous coronary intervention (PPCI). UFH pretreatment is intended to lessen the thrombotic burden, but there have been conflicting study findings on its safety and efficacy. We assessed the risks and benefits of UFH pretreatment with a retrospective analysis of registry data from the STEMI network of a German metropolitan region.
Methods: Data from patients with STEMI referred for PPCI from 2005 to 2020 were evaluated with an adjusted outcome analysis, including propensity score matching (PSM). The endpoints included the patency of the infarct-related artery (IRA) after PPCI, in-hospital mortality, access-site bleeding, and the peak creatine kinase (CK) level.
Results: We assessed data from 4632 patients with STEMI: 4420 (95.4%) were pretreated with UFH, and 212 (4.6%) were not. After PSM of 511 vs. 187 patients, the adjusted odds ratios for the various endpoints were (pretreatment vs. no pretreatment, with 95% confidence intervals): for impaired flow of the IRA, 1.01 [0.59; 1.74]; for in-hospital mortality, 1.46 [0.88; 2.42]; and for access-site bleeding, 0.59 [0.14; 2.46]. The peak creatine kinase levels were similar in the two groups (median, 1248.0 vs. 1376.5 U/L, estimated difference -134 [-611; 341]).
Conclusion: UFH pretreatment was less frequently performed in STEMI patients who had undergone cardiopulmonary resuscitation. UFH pretreatment was not associated with increased access site bleeding, nor was it found to have significantly higher efficacy with respect to the relevant endpoints. The risks and benefits of UFH pretreatment should be weighed individually in each case, as evidence from high-quality clinical trials is lacking. Data from the existing literature suggest that no pretreatment is an option to be considered, as are certain alternative antithrombotic strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3238/arztebl.m2024.0212 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized trial of low-dose thrombolysis, ultrasound-assisted thrombolysis, or heparin for intermediate-high risk pulmonary embolism-the STRATIFY trial: design and statistical analysis plan.
Trials
December 2024
Department of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Background: Intermediate-high risk pulmonary embolism (PE) carries a significant risk of hemodynamic deterioration or death. Treatment should balance efficacy in reducing clot burden with the risk of complications, particularly bleeding. Previous studies on high-dose, short-term thrombolysis with alteplase (rtPA) showed a reduced risk of hemodynamic deterioration but no change in mortality and increased bleeding complications.
View Article and Find Full Text PDFPopulation pharmacokinetics of unfractionated heparin and multivariable analysis of activated clotting time in patients undergoing radiofrequency ablation of atrial fibrillation.
Biomed Pharmacother
December 2024
Université de Reims Champagne Ardenne, UR 3801 PPF, Reims, 51100, France; Centre Hospitalier Universitaire de Reims, Service Pharmacologie-Toxicologie, Pôle de Biologie Territoriale, Reims, 51100, France. Electronic address:
Article Synopsis
- - The study aimed to create a population pharmacokinetic-pharmacodynamic (PK-PD) model to understand how different factors influence the variability of unfractionated heparin (UFH) doses in patients undergoing radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF).
- - Analysis of medical records from 668 patients revealed that pretreatments with anticoagulants like dabigatran, warfarin, or fluindione affected baseline activated clotting time (ACT), and the initial UFH dose and previous anticoagulant were key predictors of ACT 15 minutes after UFH administration.
- - The researchers successfully developed predictive calculators for ACT and UFH doses, promoting tailored anticoagulation
Background: Patients with ST-segment elevation myocardial infarction (STEMI) are often pretreated with unfractionated heparin (UFH) before a primary percutaneous coronary intervention (PPCI). UFH pretreatment is intended to lessen the thrombotic burden, but there have been conflicting study findings on its safety and efficacy. We assessed the risks and benefits of UFH pretreatment with a retrospective analysis of registry data from the STEMI network of a German metropolitan region.
View Article and Find Full Text PDFHeparin pretreatment in ST segment elevation myocardial infarction: a systematic review and meta-analysis.
Coron Artery Dis
January 2025
Serviço de Cardiologia, Centro Hospitalar e Universitário de Coimbra.
Background: Unfractionated heparin (UFH) is frequently administered before percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI). Current guidelines, however, do not provide clear recommendations for UFH pretreatment before arrival at the coronary catheterization laboratory.
Methods: Between June and July 2023, we systematically searched PubMed , Embase , and Cochrane databases for studies comparing UFH pretreatments in patients with STEMI.
Early unfractionated heparin treatment in patients with STEMI - trial design and rationale.
PLoS One
May 2024
Department of intensive internal medicine, University Medical Center Ljubljana, Ljubljana, Slovenia.
The early unfractionated heparin (UFH) treatment in patients with ST-elevation myocardial infarction (STEMI) is a single-center, open-label, randomized controlled trial. The study population are patients with STEMI that undergo primary percutaneous coronary intervention (PPCI). The trial was designed to investigate whether early administration of unfractionated heparin immediately after diagnosis of STEMI is beneficial in terms of patency of infarct-related coronary artery (IRA) when compared to established UFH administration at the time of coronary intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!